Table 2.
List of studies included in meta‐analysis
| Study | Intervention | Dose per week of IV iron | Control | Dose per week of IV iron |
|---|---|---|---|---|
| DeVita et al.20 | n = 19; IV iron dextran up to 1 g to maintain SF 400 ng/mL; ESA to maintain Hct 32.5–36% | Mean (SD) total iron dose
1650.0 (981.2) mg Given as 100 mg per dialysis session |
n = 17; IV iron dextran up to 1 g to maintain SF 200 ng/mL; ESA to maintain Hct 32.5–36% | Mean (SD) total iron dose
906.7 (953.1) mg Given as 100 mg/r dialysis session |
| Fishbane et al.21 | n = 64; IV iron dextran to maintain SF ≥ 100 μg/L and TSAT ≥20%; ESA to maintain Hct 33–36% | Mean (SD) dose per wk
47.7 (35.5) mg Given as 100 mg per dialysis session |
n = 74; IV iron to maintain CHr ≥ 30 pg; ESA to maintain Hct 33–36% | Mean (SD) dose per wk
22.9 (20.5) mg Given as 100 mg per dialysis session |
| Fishbane et al.22 | n = 20; IV iron dextran 100 mg twice per wk; ESA to maintain Hct 30–34% |
Not reported Given as 200 mg/wk |
n = 32; oral iron; ESA to maintain Hct 30–34 % | Oral iron |
| Kaneko et al.23 | n = 100; IV iron colloid 40 mg 3 x/wk if TSAT <20 %; ESA to maintain Hct 29.5–32.5 % | Mean (SD) total iron at wk 16
377.5 (361.6) mg Given as 120 mg/wk |
n = 97 IV iron colloid 40 mg three times per wk if Chr < 32.5 pg; ESA to maintain Hct 29.5–32.5% | Mean (SD) total iron at wk 16
267.7 (353.2) mg Given as 120 mg/wk |
| Kotaki et al.24 | n = 15; IV iron (not specified) 100 mg/wk; ESA to maintain Hct within three points of baseline |
Not reported Given as 100 mg/wk |
n = 16; oral iron; ESA to maintain Hct within three points of baseline | Oral iron |
| Li and Wang25 | n = 70; IV iron sucrose 100 mg twice/wk; ESA reduced by 25% if Hb ≥ 11.0 g/dL |
Not reported Given as 100–200 mg/wk |
n = 66; oral iron; ESA reduced by 25% if Hb ≥ 11.0 g/dL | Oral iron |
| Macdougall et al.26 | n = 12; IV iron dextran 250 mg every 2 weeks; ESA reduced by 33% if Hb > 12.0 g/dL, otherwise ESA dose increased by 100% if Hb increased <1 g/dL at 8 weeks |
Not reported Given as 250 mg every 2 weeks |
n = 13; oral iron; ESA reduced by 33% if Hb > 12.0 g/dL, otherwise ESA dose increased by 100% if Hb increased <1 g/dL at 8 weeks n = 12; no iron; ESA reduced by 33% if Hb >12.0 g/dL, otherwise ESA dose increased by 100% if Hb increased <1 g/dL at 8 weeks | Oral iron or no iron |
CHr, reticulocyte haemoglobin content; ESA, erythropoietin stimulating agent; Hb, haemoglobin, Hct, haematocrit; HD, haemodialysis; IV, intravenous; SF, serum ferritin; TSAT, transferrin saturation; wk, week.